BidaskClub upgraded shares of Celldex Therapeutics (NASDAQ:CLDX) from a sell rating to a hold rating in a research report sent to investors on Tuesday morning.
Other research analysts have also recently issued reports about the stock. HC Wainwright set a $10.00 price target on shares of Celldex Therapeutics and gave the company a buy rating in a research report on Friday, February 9th. WBB Securities reissued a buy rating and set a $10.00 price target on shares of Celldex Therapeutics in a research report on Wednesday, December 6th. Two equities research analysts have rated the stock with a sell rating, three have issued a hold rating and five have assigned a buy rating to the stock. Celldex Therapeutics currently has a consensus rating of Hold and an average price target of $6.38.
Shares of Celldex Therapeutics (NASDAQ:CLDX) opened at $2.82 on Tuesday. The firm has a market cap of $393.24, a PE ratio of -3.20 and a beta of 2.63. Celldex Therapeutics has a 52 week low of $2.20 and a 52 week high of $3.75.
A number of hedge funds and other institutional investors have recently modified their holdings of CLDX. Cubist Systematic Strategies LLC purchased a new position in Celldex Therapeutics during the 3rd quarter valued at about $101,000. OxFORD Asset Management LLP purchased a new position in Celldex Therapeutics during the 3rd quarter valued at about $122,000. Teacher Retirement System of Texas raised its holdings in Celldex Therapeutics by 325.0% in the fourth quarter. Teacher Retirement System of Texas now owns 43,253 shares of the biopharmaceutical company’s stock worth $123,000 after buying an additional 33,077 shares during the last quarter. Voya Investment Management LLC raised its holdings in Celldex Therapeutics by 17.4% in the second quarter. Voya Investment Management LLC now owns 50,535 shares of the biopharmaceutical company’s stock worth $125,000 after buying an additional 7,499 shares during the last quarter. Finally, MetLife Investment Advisors LLC purchased a new position in Celldex Therapeutics in the fourth quarter worth about $187,000. 57.55% of the stock is owned by institutional investors.
COPYRIGHT VIOLATION WARNING: “Celldex Therapeutics (CLDX) Upgraded by BidaskClub to Hold” was posted by Ticker Report and is owned by of Ticker Report. If you are viewing this report on another site, it was illegally copied and republished in violation of United States and international copyright & trademark legislation. The correct version of this report can be read at https://www.tickerreport.com/banking-finance/3252336/celldex-therapeutics-cldx-upgraded-by-bidaskclub-to-hold.html.
Celldex Therapeutics Company Profile
Celldex Therapeutics, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of several immunotherapy technologies for the treatment of cancer and other diseases. Its lead drug Rintega (also referred to as rindopepimut and CDX-110) is a therapeutic vaccine, which is meant for the treatment of glioblastoma patients.
Receive News & Ratings for Celldex Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celldex Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.